These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30392824)

  • 1. Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment.
    Frerichs KA; Bosman PWC; Nijhof IS; Zweegman S; van de Donk NWCJ
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e9-e11. PubMed ID: 30392824
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens.
    De Novellis D; Fontana R; Serio B; Vaccaro E; Guariglia R; Morini D; Rizzo M; Giudice V; Selleri C
    Cancer Med; 2024 Jul; 13(14):e7402. PubMed ID: 39034465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytomegalovirus infection during daratumumab therapy in patients with newly diagnosed multiple myeloma.
    Kikuchi T; Tsukada N; Kunisada K; Nomura-Yogo M; Oda Y; Sato K; Takei T; Ogura M; Abe Y; Suzuki K; Ishida T
    Int J Hematol; 2024 Jul; 120(1):91-95. PubMed ID: 38639848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single-centre retrospective study.
    Ge AY; Huang CY; Banerjee R; Knoche J; Chung A; Arora S; Martin TG; Wolf J; Wong SW; Wiita AP; Shah N
    Br J Haematol; 2023 Jun; 201(5):935-939. PubMed ID: 36846905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution.
    Matsunaga N; Suzuki T; Nishitarumizu N; Nakanishi Y; Kondo A; Kato Y; Ebina T; Marumo Y; Nakamura T; Nakashima T; Kinoshita S; Narita T; Ri M; Kusumoto S; Komatsu H; Iida S
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):531-536.e1. PubMed ID: 38653670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens.
    Tabata R; Sato N; Yamauchi N; Guo YM; Nakamura H; Nagata A; Song-Gi C; Minami Y; Yuda J
    Ann Hematol; 2022 Feb; 101(2):465-467. PubMed ID: 33864134
    [No Abstract]   [Full Text] [Related]  

  • 7. [Daratumumab for multiple myeloma].
    Croizier C; Bailly S
    Bull Cancer; 2018 Nov; 105(11):985-991. PubMed ID: 30430991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma.
    Nakagawa R; Onishi Y; Kawajiri A; Onodera K; Furukawa E; Sano S; Saito K; Ichikawa S; Fujiwara T; Fukuhara N; Harigae H
    Ann Hematol; 2019 Aug; 98(8):1999-2001. PubMed ID: 30824957
    [No Abstract]   [Full Text] [Related]  

  • 9. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma.
    Sanchez L; Wang Y; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jun; 9(1):51. PubMed ID: 27363983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infectious and immunological sequelae of daratumumab in multiple myeloma.
    Johnsrud AJ; Johnsrud JJ; Susanibar SA; Kamimoto JJ; Kothari A; Burgess M; Van Rhee F; Rico JC
    Br J Haematol; 2019 Apr; 185(1):187-189. PubMed ID: 29974956
    [No Abstract]   [Full Text] [Related]  

  • 11. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
    Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
    Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
    Courville EL; Yohe S; Shivers P; Linden MA
    Am J Clin Pathol; 2020 Jan; 153(2):221-228. PubMed ID: 31679012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Daratumumab--breakthrough drug in multiple myeloma therapy].
    Jurczyszyn A; Kosmaczewska A; Skotnicki AB
    Postepy Hig Med Dosw (Online); 2014 Nov; 68():1352-60. PubMed ID: 25531698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis.
    Pick M; Vainstein V; Goldschmidt N; Lavie D; Libster D; Gural A; Grisariu S; Avni B; Ben Yehuda D; Gatt ME
    Eur J Haematol; 2018 May; 100(5):494-501. PubMed ID: 29453884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by
    Wang Y; Zhang Y; Hughes T; Zhang J; Caligiuri MA; Benson DM; Yu J
    Clin Cancer Res; 2018 Aug; 24(16):4006-4017. PubMed ID: 29666301
    [No Abstract]   [Full Text] [Related]  

  • 17. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma.
    Kumar S; Durie B; Nahi H; Vij R; Dimopoulos MA; Kastritis E; Terpos E; Leleu X; Beksac M; Goldschmidt H; Hillengass J; Su Z; Hutton B; Cameron C; Khan I; Lam A
    Leuk Lymphoma; 2019 Jan; 60(1):163-171. PubMed ID: 29741423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.
    Lovas S; Varga G; Farkas P; Masszi T; Wohner N; Bereczki Á; Adamkovich N; Borbényi Z; Szomor Á; Alizadeh H; Szaleczky E; Wolf K; Schneider T; Plander M; Szendrei T; Csacsovszki O; Csukly Z; Rajnics P; Egyed M; Nagy Z; Rejtő L; Illés Á; Mikala G; Váróczy L
    Int J Hematol; 2019 Nov; 110(5):559-565. PubMed ID: 31392600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.
    Salomon-Perzyński A; Walter-Croneck A; Usnarska-Zubkiewicz L; Dytfeld D; Zielińska P; Wojciechowska M; Hołojda J; Robak P; Pasternak A; Knopińska-Posłuszny W; Hawrylecka D; Wójtowicz M; Szeremet A; Osowiecki M; Mordak-Domagała M; Zaucha JM; Giannopoulos K; Warzocha K; Jamroziak K
    Adv Med Sci; 2019 Sep; 64(2):349-355. PubMed ID: 31125864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.